Related News

No related news articles were found.

dr. reddy's laboratories (DRRD) Related Businessweek News

No Related Businessweek News Found

dr. reddy's laboratories (DRRD) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company in India. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment is also engaged in the operation of biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment is involved in the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. Its differentiated formulations portfolio consists of new, synergistic combinations, and technologies that enhance safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment is also involved in the Company’s specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The company’s therapeutic categories include gastro-intestinal, cardiovascular, pain management, and oncology. It also operates in North America, Europe, Russia, other countries of the former Soviet Union, and internationally. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

Dr Reddy's Laboratories announced it has entered into an agreement with Hetero to allow the company to distribute and market chronic Hepatitis C drug Sofosbufir 400 mg tablets, manufactured by Hetero, under the brand name Resof in India. Clinical studies have indicated that Sofosbuvir 400 mg in combination with other agents achieved high cure rates while shortening treatment duration to 12 weeks and reducing or completely eliminating the need for Interferon injections, depending on the viral genotype. According to the World health Organization, close to 12 million Indians suffer from chronic Hepatitis C, a disease that can seriously affect the liver, leading to potentially lifethreatening complications, including liver cancer. Earlier this month, two citybased pharma players, Natco Pharma Limited and Hetero, got approval to manufacture and market generic Sofosbuvir tablets 400 mg, from the Drugs Controller General of India. Sofosbuvir is sold globally by Gilead Sciences Inc. under the Sovaldi brand name. Both the Indian companies had announced that they will market generic Sofosbuvir at a price of INR 19,900 for a bottle of 28 tablets.

Dr. Reddy's Laboratories Ltd. has announced that its custom pharmaceutical services division has created a new formulation development laboratory in Miyapur, Hyderabad, India. Bringing together the existing API development team and the formulation teams at one location will accelerate project timelines, reduce costs and simplify licensing processes for CPS' pharma customers. With this expansion, the laboratories will form a Center of Excellence for fully integrated API and formulation development services, including pre-formulation studies, prototype formulation development, process development and optimization. These development capabilities will seamlessly integrate CPS' offerings of cGMP supplies for clinical trials, registration batches and commercial manufacture.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.